Quince therapeutics completes acquisition of erydel s.p.a.

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of erydel s.p.a., a privately-held, late-stage biotech company. quince's newly acquired phase 3 lead asset, erydex, targets a rare neurodegenerative disease, ataxia-telangiectasia (a-t). current.
QNCX Ratings Summary
QNCX Quant Ranking